User login
Key clinical point: Denosumab improves bone-related outcomes in women with high-risk early-stage breast cancer.
Major finding: Denosumab was associated with longer time to first bone metastasis in patients younger than 50 years (hazard ratio [HR], 0.70; P = .018) and in premenopausal women (HR, 0.74; P = .038). Denosumab also delayed the risk for first fracture (HR, 0.76; P = .004) and first skeletal-related event (HR, 0.52; P = .001).
Study details: An exploratory analysis of randomized, placebo-controlled phase 3 D-CARE trial of 4,509 patients with stage II/III breast cancer randomly assigned to receive adjuvant/neoadjuvant chemotherapy with either denosumab or placebo.
Disclosures: This study was funded by Amgen Inc. Dr. R Coleman received lecture funding, steering committee fees, and travel expenses from various sources and reported stock ownership in Inbiomotion. Dr. Y. Zhou, Dr. D. Jandial, and Dr. B. Cadieux were employees of and/or shareholders in Amgen. The other authors have no competing interest.
Source: Coleman R et al. Adv Ther. 2021 Jun 29. doi: 10.1007/s12325-021-01812-9.
Key clinical point: Denosumab improves bone-related outcomes in women with high-risk early-stage breast cancer.
Major finding: Denosumab was associated with longer time to first bone metastasis in patients younger than 50 years (hazard ratio [HR], 0.70; P = .018) and in premenopausal women (HR, 0.74; P = .038). Denosumab also delayed the risk for first fracture (HR, 0.76; P = .004) and first skeletal-related event (HR, 0.52; P = .001).
Study details: An exploratory analysis of randomized, placebo-controlled phase 3 D-CARE trial of 4,509 patients with stage II/III breast cancer randomly assigned to receive adjuvant/neoadjuvant chemotherapy with either denosumab or placebo.
Disclosures: This study was funded by Amgen Inc. Dr. R Coleman received lecture funding, steering committee fees, and travel expenses from various sources and reported stock ownership in Inbiomotion. Dr. Y. Zhou, Dr. D. Jandial, and Dr. B. Cadieux were employees of and/or shareholders in Amgen. The other authors have no competing interest.
Source: Coleman R et al. Adv Ther. 2021 Jun 29. doi: 10.1007/s12325-021-01812-9.
Key clinical point: Denosumab improves bone-related outcomes in women with high-risk early-stage breast cancer.
Major finding: Denosumab was associated with longer time to first bone metastasis in patients younger than 50 years (hazard ratio [HR], 0.70; P = .018) and in premenopausal women (HR, 0.74; P = .038). Denosumab also delayed the risk for first fracture (HR, 0.76; P = .004) and first skeletal-related event (HR, 0.52; P = .001).
Study details: An exploratory analysis of randomized, placebo-controlled phase 3 D-CARE trial of 4,509 patients with stage II/III breast cancer randomly assigned to receive adjuvant/neoadjuvant chemotherapy with either denosumab or placebo.
Disclosures: This study was funded by Amgen Inc. Dr. R Coleman received lecture funding, steering committee fees, and travel expenses from various sources and reported stock ownership in Inbiomotion. Dr. Y. Zhou, Dr. D. Jandial, and Dr. B. Cadieux were employees of and/or shareholders in Amgen. The other authors have no competing interest.
Source: Coleman R et al. Adv Ther. 2021 Jun 29. doi: 10.1007/s12325-021-01812-9.